A user shared their 4-month progress using a topical solution with 5% minoxidil and 0.1% finasteride, applied twice daily. They reported good results despite occasional missed applications.
The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.
Topical finasteride reduces scalp DHT effectively, with a suggested application of 1.5ml of 0.03% daily. It binds to scalp enzymes, potentially requiring daily or every other day application for sustained results.
Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.
A user shared their 4-month progress using a serum with Minoxidil 10%, Progesterone, Azelaic acid, Retinoic acid, Latanoprost, and Hydrocortisone, along with PRP and Fotona laser treatments. They are pleased with the results and plan to continue with more PRP and laser sessions, without using Finasteride.
The conversation is about a topical spray containing finasteride, minoxidil, and tretinoin, with users discussing its effectiveness compared to more established brands. One user mentions using a product with 5% minoxidil, 0.15% finasteride, and 0.15% tretinoin.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
The user is considering topical Saw Palmetto or Pumpkin Seed Oil due to sensitivity to finasteride and cost issues. They also use dermastamping for Minoxidil absorption and seek advice on timing to avoid systemic absorption.
PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.
Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.
The conversation discusses concerns about RU58841 degrading when exposed to light and transferring pyri to a dark glass bottle to prevent this. The user keeps the pyri out for only two minutes before storing it in a dark place.
Mixing topical solutions like Morr F 10% (Minoxidil) and L'Oreal Seryoxyl (Stemoxydine) before application may not reduce their effectiveness. The goal is to apply treatments all at once instead of multiple times a day.
Mixing topical finasteride with essengen f and stemoxydine creates 0.25mg dose in 2ml. Minoxidil max suggests mixing 8.5ml essengen f with 60ml solvent for 0.25mg dose in 1ml.
The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.
The user noticed new baby hairs after using sulforaphane but is still experiencing shedding. They are seeking a supplement to stop shedding, possibly grape seed extract.
The user experienced hair regrowth and improved hair quality using topical minoxidil on temples and oral finasteride daily. They also noted thicker eyebrows and some side effects like minor erectile dysfunction.
User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.
A new hair growth spray in the UK contains finasteride 0.3%, minoxidil 5%, and tretinoin 0.01%, but some users find the finasteride concentration too high. Another brand offers a similar spray with a lower finasteride dose at a cheaper price, and some users report scalp irritation from the new spray.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
The conversation discusses using minoxidil foam as a solvent for topical finasteride. Ingredients of minoxidil foam include butane, cetyl alcohol, glycerin, and purified water.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
OP is considering mixing finasteride pills with a 60ml bottle of Redensyl to create a topical treatment. The discussion focuses on the feasibility and effectiveness of this approach for hair loss.
The user is concerned about the effectiveness of a prescribed topical finasteride spray, Alocare, when applied to the scalp. They are unsure if hair might block the solution and reduce its effectiveness.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
The conversation discusses the pros and cons of using propylene glycol versus ethyl alcohol in topical solutions for finasteride and minoxidil. It questions why propylene glycol is commonly used and whether ethyl alcohol might be a better option.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.
Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.